NEW YORK (GenomeWeb News) - Transgenomic today said third-quarter revenues decreased 26 percent as R&D spending rose 15 percent and income turned swung to a loss.
 
Total receipts for the three months ended Sept. 30 decreased to $4.9 million from $6.7 million year over year.
 
"We were very disappointed in our sales," CEO and President Craig Tuttle said. The company added that it has hired Thomas Weisel Partners to help it figure out how to “maximize shareholder value” in the short- and long-term.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.